HER2 targeting as a two-sided strategy for breast cancer diagnosis and treatment: Outlook and recent implications in nanomedical approaches

Pharmacological Research

Volumn 62, Issue 2, 2010, Pages 150-165

  Colombo, Miriam ^a,b   Corsi, Fabio ^b   Foschi, Diego ^b   Mazzantini, Elisa ^a   Mazzucchelli, Serena ^a,b   Morasso, Carlo ^c   Occhipinti, Emanuela ^a   Polito, Laura ^c   Prosperi, Davide ^a,c   Ronchi, Silvia ^c   Verderio, Paolo ^a,b  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c CNR   (Italy)

Author keywords

Antibodies; Breast cancer; Growth factors; Nanomedicine; Nanoparticles; Theranostic agents

Indexed keywords

4 [3 CHLORO 4 (2 PYRIDINYLMETHOXY)ANILINO] 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE; 8 QUINOLINOL; CARBOPLATIN; CD24 ANTIGEN; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GOLD NANOPARTICLE; HERMES ANTIGEN; LAPATINIB; MACROGOL; MACROGOL 8000; MAGNETIC NANOPARTICLE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; POLYGLACTIN; POLYLACTIC ACID; RAPAMYCIN; SMALL INTERFERING RNA; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TRANSFORMING GROWTH FACTOR ALPHA; TRASTUZUMAB; MONOCLONAL ANTIBODY; NANOPARTICLE;

ACUTE GRANULOCYTIC LEUKEMIA; BREAST CANCER; BREAST CARCINOMA; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GENE THERAPY; CANCER INHIBITION; CANCER RESISTANCE; CANCER STEM CELL; CARDIOTOXICITY; CELL CYCLE ARREST; CLINICAL TRIAL; CYTOTOXICITY; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TARGETING; GENE SILENCING; HUMAN; HYPERTHERMIC THERAPY; METASTASIS; MONOTHERAPY; NANOBIOTECHNOLOGY; NANOIMAGING; NATURAL KILLER CELL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SOLID TUMOR; TOXICITY TESTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CHEMISTRY; DIAGNOSTIC USE; FEMALE; METABOLISM; NANOMEDICINE; PROCEDURES; TRENDS;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; FEMALE; HUMANS; NANOMEDICINE; NANOPARTICLES; RECEPTOR, ERBB-2; ANTIBODIES, MONOCLONAL, HUMANIZED;

EID: 77953687871     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2010.01.013     Document Type: Review

References (173)

1. Parker S.L., Tong T.A., Bolden S., Wingo P.A. Cancer statistics. CA Cancer J Clin 1996, 46:5-27. [CA Cancer J Clin 1996;46:3-4].
2. Veronesi U., Paganelli G., Galimberti V., Viale G., Zurrida S., Bedoni M., et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 1997, 349:1864-1867.
3. Batist G., Ramakrishman G., Rao R.S., Chandrasekharan A., Gutheil J., Guthrie T., et al. In vivo cancer targeting and imaging with semiconductor quantum dots. J Clin Oncol 2001, 19:1444-1454.
4. Gao X., Cui Y., Levenson R.M., Chung L.W.K., Nie S. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. Nat Biotechnol 2004, 22:969-976.
5. Gradishar W.J., Tjulandin S., Davidson N., Shaw H., Desai N., Bhar P., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005, 23:7794-7803.
6. Park W.J. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res 2002, 4:95-99.
7. Lee C.C., MacKay J.A., Frechet J.M., Szoka F.C. Designing dendrimers for biological applications. Nat Biotechnol 2005, 23:1517-1526.
8. Tasis D., Tagmatarchis N., Bianco A., Prato M. Chemistry of carbon nanotubes. Chem Rev 2006, 106:1105-1136.
9. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003, 2:347-360.
10. Yezhelyev M.V., Gao X., Xing Y., Al-Hajj A., Nie S., O'Regan R.M. Emerging use of nanoparticles in diagnosis and treatment of breast cancer. Lancet Oncol 2006, 7:657-667.
11. Jain K. Personalised medicine for cancer: from drug development into clinical practice. Expert Opin Pharmacother 2005, 6:1463-1476.
12. Ferrari M. Nanogeometry: beyond drug delivery. Nat Nanotech 2008, 3:131-132.
13. Jiang W., KimBetty Y.S., Rutka J.T., Chan W.C.W. Nanoparticle-mediated cellular response is size-dependent. Nat Nanotech 2008, 3:145-150.
14. Tasciotti E., Liu X., Bhavane R., Plant K., Leonard A.D., Price B.K., et al. Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat Nanotech 2008, 3:151-157.
15. Gratton S.E.A., Ropp P.A., Pohlhaus P.D., Luft J.C., Madden V.J., Napier M.E., et al. The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci USA 2008, 105:11613-11618.
16. Corsi F., De Palma C., Colombo M., Allevi R., Nebuloni M., Ronchi S., et al. Towards ideal magnetofluorescent nanoparticles for bimodal detection of breast-cancer cells. Small 2009, 5:2555-2564.
17. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., et al. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 1989, 244:707-712.
18. Olayioye M.A., Neve R.M., Lane H.A., Hynes N.E. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000, 19:3159-3167.
19. Ferguson K.M., Berger M.B., Mendrola J.M., Cho H.S., Leahy D.J., Lemmon M.A. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell 2003, 11:507-517.
20. Ogiso H., Ishitani R., Nureki O., Fukai S., Yamanaka M., Kim J.H., et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 2002, 110:775-787.
21. Hynes N.E., Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005, 5:341-354.
22. Burgess A.W., Cho H.S., Eigenbrot C., Ferguson K.M., Garrett T.P.J., Leahy D.J., et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 2003, 12:541-552.
23. Garrett T.P., McKern N.M., Lou M., Elleman T.C., Adams T.E., Lovrecz G.O., et al. The crystal structure of truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell 2003, 11:495-505.
24. Citri A., Yarden Y. EGF-ERBB signalling: towards the system level. Nat Rev Mol Cell Biol 2006, 7:505-516.
25. Sharma S.V., Settleman J. ErbBs in lung cancer. Exp Cell Res 2009, 315:557-571.
26. Wieduwilt M.J., Moasser M.M. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci 2008, 65:1566-1584.
27. Amit I., Wides R., Yarden Y. Evolvable signalling networks of receptor tyrosine kinase: relevance of robustness to malignancy and to cancer therapy. Mol Syst Biol 2007, 3:151.
28. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 2002, 296:1655-1657.
29. Engelman J.A., Luo J., Cantley L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006, 7:606-619.
30. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat Rev Cancer 2002, 2:489-501.
31. Yuan T.L., Cantley L.C. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008, 27:5497-5510.
32. Nagata Y., Lan K.H., Zhou X., Esteva L.J., Sahin A.A., Klos K.S., et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6:117-127.
33. Faltus T., Yuan J., Zimmer B., Kramer A., Loibl S., Kaufmann M., et al. Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells. Neoplasia 2004, 6:786-795.
34. Clifford A., Hudis M.D. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007, 357:39-51.
35. Cooley S., Burns L.J., Repka T., Miller J.S. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Exp Hematol 1999, 27:1533-1541.
36. Lewis G.D., Figari I., Fendly B., Wong W.L., Carter P., Gorman C., et al. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 1993, 37:255-263.
37. 2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res 1998, 58:5123-5129.
38. Molina M.A., Codony-Servat J., Albanell J., Rojo F., Arribas J., Baselga J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 2001, 61:4744-4749.
39. Sarup J.C., Johnson R.M., King K.L., Fendly B.M., Lipari M.T., Napier M.A., et al. Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth Regul 1991, 1:72-82.
40. Valabrega G., Montemurro F., Sarotto I., Petrelli A., Rubini P., Tacchetti C., et al. TGFα expression impairs trastuzumab-induced HER2 downregulation. Oncogene 2005, 24:3002-3010.
41. Austin C.D., De Maziere A.M., Pisacane P.I., van Dijk S.M., Eigenbrot C., Sliwkowski M.X., et al. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell 2004, 15:5268-5282.
42. Delord J.P., Allal C., Canal M., Mery E., Rochaix P., Hennebelle I., et al. Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma. Ann Oncol 2005, 16:1889-1897.
43. Lane H.A., Motoyama A.B., Beuvink I., Hynes N.E. Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling. Ann Oncol 2001, 12:S21-S22.
44. Zhang H., Drebin J., Murali R., Greene M.I. ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest 2006, 117:2051-2058.
45. Wang S.E., Narasanna A., Perez-Torres M., Xiang B., Wu F.Y., Yang S., et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 2006, 10:25-38.
46. Diermeier S., Horvath G., Knuechel-Clarke R., Hofstaedter F., Szollosi J., Brockhoff G. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Exp Cell Res 2005, 304:604-619.
47. Nahta R., Yuan L.X., Zhang B., Kobayashi R., Esteva F.J. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005, 65:11118-11128.
48. Nagy P., Friedlander E., Tanner M., Kapanen A.I., Carraway K.L., Isola J., et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 2005, 65:473-482.
49. Gilboa L., Ben-Levy R., Yarden Y. Roles for a cytoplasmic tyrosine and tyrosine kinase activity in the interactions of Neu receptors with coated pits. J Biol Chem 1995, 270:7061-7067.
50. Maier L.A., Xu F.J., Hester S., Boyer C.M., McKenzie S., Bruskin A.M., et al. Requirements for the internalization of a murine monoclonal antibody directed against the HER-2/neu gene product c-erbB-2. Cancer Res 1991, 51:5361-5369.
51. Qian X., O'Rourke D.M., Drebin J., Zhao H., Wang Q., Greene M.I. Identification of p185neu sequences required for monoclonal antibody- or ligand-mediated receptor signal attenuation. DNA Cell Biol 1997, 16:1395-1405.
52. Srinivas U., Tagliabue E., Campiglio M., Menard S., Colnaghi M.I. Antibody-induced activation of p185HER2 in the human lung adenocarcinoma cell line Calu-3 requires bivalency. Cancer Immunol Immunother 1993, 36:397-402.
53. Osipo C., Patel P., Rizzo P., Clementz A.G., Hao L., Golde T.E., et al. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor. Oncogene 2008, 27:5019-5032.
54. Dievart A., Beaulieu N., Jolicoeur P. Involvement of Notch1 in the development of mouse mammary tumors. Oncogene 1999, 18:5973-5981.
55. Politi K., Feirt N., Kitajewski J. Notch in mammary gland development and breast cancer. Semin Cancer Biol 2004, 14:341-347.
56. Bedard P.L., Cardoso F., Piccart-Gebhart M.J. Stemming resistance to HER-2 targeted therapy. J Mammary Gland Biol Neoplasia 2009, 14:55-66.
57. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3:730-737.
58. Behbod F., Rosen J.M. Will cancer stem cells provide new therapeutic targets?. Carcinogenesis 2004, 26:703-711.
59. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., Caceres-Cortes J., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648.
60. Xiao Y., Ye Y., Yearsley K., Jones S., Barsky S.H. The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype. Am J Pathol 2008, 173:561-574.
61. Palyi-Krekk Z., Barok M., Isola J., Tammi M., Szollosi J., Nagy P. Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer. Eur J Cancer 2007, 43:2423-2433.
62. Bullock K., Blackwell K. Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer. Oncologist 2008, 13:515-525.
63. Spector N.L., Xia W., Burris H. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 2005, 23:2502-2512.
64. O'Shaugnessy J.K., Blackwell L., Burstein H., Storniolo A.M., Sledge G., Baselga J., et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. J Clin Oncol 2008, 26(Suppl.):1015.
65. Agus D.B., Akita R.W., Fox W.D., Lewis G.D., Higgins B., Pisacane P.I., et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002, 2:127-137.
66. Cho H.S., Mason K., Ramyar K.X., Stanley A.M., Gabelli S.B., Denney D.W., et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003, 421:756-760.
67. Nahta R., Hung M.C., Esteva F.J. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 2004, 64:2343-2346.
68. Gelmon K.A., Fumoleau P., Verma S., Wardley A.M., Conte P.F., Miles D., et al. Results of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy. J Clin Oncol 2008, 26(Suppl.):1026.
69. Dancey J., Sausville E.A. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2003, 2:296-313.
70. Neshat M.S., Mellinghtoff I.K., Tran C., Stiles B., Thomas G., Petersen R., et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 2001, 98:10314-10319.
71. Shinkawa T., Nakamura K., Yamane N., Shoji-Hosaka E., Kanda Y., Sakurada M., et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003, 278:3466-3473.
72. Niwa R., Hatanaka S., Shoji-Hosaka E., Sakurada M., Kobayashi Y., Uehara A., et al. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcγRIIIa functional polymorphism. Clin Cancer Res 2004, 10:6248-6255.
73. Suzuki E., Niwa R., Saji S., Muta M., Hirose M., Iida S., et al. A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients. Clin Cancer Res 2007, 13:1875-1882.
74. Batra J.K., Kasprzyk P.G., Bird R.E., Pastan I., King C.R. Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin. Proc Natl Acad Sci USA 1992, 89:5867-5871.
75. Rosenblum M.G., Horn S.A., Cheung L.H. A novel recombinant fusion toxin targeting HER-2/NEU-over-expressing cells and containing human tumor necrosis factor. Int J Cancer 2000, 88:267-273.
76. Nahta R., Esteva F.J. Herceptin: mechanisms of action and resistance. Cancer Lett 2006, 232:123-138.
77. Wong K.K., Fracasso P.M., Bukowski R.M., Lynch T.J., Munster P.N., Shapiro G.I., et al. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res 2009, 15:2552-2558.
78. + breast cancer. Cancer Res 2009, 69(Suppl.):725.
79. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
80. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005, 5:275-284.
81. Jones R.J., Matsui W.H., Smith B.D. Cancer stem cells: are we missing the target?. J Natl Cancer Inst 2004, 96:583-585.
82. Donnenberg V.S., Donnenberg A.D. Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol 2005, 45:872-877.
83. Guzman M.L., Jordan C.T. Considerations for targeting malignant stem cells in leukemia. Cancer Control 2004, 11:97-104.
84. Zhou J., Zhang H., Gu P., Bai J., Margolick J.B., Zhang Y. NF-kappaB pathway inhibitors preferentially inhibit breast cancer stem-like cells. Breast Cancer Res Treat 2008, 111:419-427.
85. Zhou J., Wulfkuhle J., Zhang H., Gu P., Yang Y., Deng J., et al. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci USA 2007, 104:16158-16163.
86. Zhou J., Zhang H., Gu P., Margolick J., Yin D., Zhang Y. Cancer stem/progenitor cell active compound 8-quinolinol in combination with paclitaxel achieves an improved cure of breast cancer in the mouse model. Breast Cancer Res Treat 2009, 115:269-277.
87. Kim Y.H., Woo K.J., Lim J.H., Kim S., Lee T.J., Jung E.M., et al. 8-Hydroxyquinoline inhibits iNOS expression and nitric oxide production by down-regulating LPSinduced activity of NF-kappaB and C/EBPbeta in Raw 264.7 cells. Biochem Biophys Res Commun 2005, 329:591-597.
88. Michalet X., Pinaud F.F., Bentolila L.A., Tsay J.M., Doose S., Li J.J., et al. Quantum dots for live cells, in vivo imaging and diagnostic. Science 2005, 307:538-544.
89. Smith A.M., Duan H., Mohs A.M., Nie S. Bioconjugated quantum dots for in Vivo molecular and cellular imaging. Adv Drug Del Rev 2008, 60:1226-1240.
90. Rhyner M.N., Smith A.M., Gao X., Mao H., Yang L., Nie S. Quantum dots and multifunctional nanoparticles: new contrast agents for tumor imaging. Nanomedicine 2006, 1:209-217.
91. Harisinghani M.G., Barentsz J., Hahn P.F., Deserno W.M., Tabatabaei S., Van de Kaa C.H., et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003, 348:2491-2499.
92. Evgenov N.V., Medarova Z., Dai G., Bonner-Weir S., Moore A. In vivo imaging of islet transplantation. Nat Med 2006, 12:144-148.
93. Barnett B.P., Arepally A., Karmarkar P.V., Qian D., Gilson W.D., Walczak P., et al. Magnetic resonance-guided, real-time targeted delivery and imaging of magnetocapsules immunoprotecting pancreatic islet cells. Nat Med 2007, 13:986-991.
94. El-Boubbou K., Gruden C., Huang X. Magnetic Glyco-nanoparticles: a unique tool for rapid pathogen detection, decontamination, and strain differentiation. J Am Chem Soc 2007, 129:13392-13393.
95. Fortin J.P., Wilhelm C., Servais J., Menager C., Bacri J.C., Gazeau F. Size-sorted anionic iron oxide nanomagnets as colloidal mediators for magnetic hyperthermia. J Am Chem Soc 2007, 129:2628-2635.
96. Lu A.H., Salabas E.L., Schlut F. Magnetic nanoparticles: synthesis, protection, functionalization, and application. Angew Chem Int Ed 2007, 46:1222-1244.
97. Laurent S., Forge D., Port M., Roch A., Robic C., Vander Elst L., et al. Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem Rev 2008, 108:2064-2110.
98. Grzelczac M., Perez-Juste J., Mulvaney P., Liz-Marzàn L.M. Shape control in gold nanoparticle synthesis. Chem Soc Rev 2008, 37:1783-1791.
99. Ghosh P., Han G., De M., Kim C.K., Rotello V.M. Gold nanoparticles in delivery application. Adv Drug Del Rev 2008, 60:1307-1315.
100. Ghosh P., Han G., De M., Kim C.K., Rotello V.M. Fluorescent core-shell silica nanoparticles: towards "Lab on a particle" architectures for nanobiotechnology. Chem Soc Rev 2006, 35:1028-1032.
101. Kang S.M., Lee K.B., Kim D.J., Choi I.S. Biomimetic approach to the formation of gold nanoparticles/silica core/shell structures and subsequent conjugation. Nanotechnology 2006, 17:4719-4725.
102. Yong S.Y., Zhang Hj, Yu J.B., Wang C., Sun L.N., Shi W.D. Bifunctional magnetic-optical nanocomposities: grafting lanthanide complex onto core-shell magnetic silica nanoarchitecture. Langmuir 2007, 23:7836-7840.
103. Yang D., Hu J., Fu S. Controlled synthesis of magnetite-silica nanocomposities via seeded sol-gel approach. J Phys Chem C 2009, 113:7646-7651.
104. Eghtedari M., Liopo A.V., Copland J.A., Oraevsky A.A., Motamedi M. Engineering of hetero-functional gold nanorods for the vivo molecular targeting of breast cancer. Nanoletters 2009, 9:287-291.
105. Wuang S.C., Neoh K.G., Kang E.N., Pack D.W., Leckband D.E. HER-2-mediated endocytosis of magnetic nanospheres and the implications in cell targeting and particle magnetization. Biomaterials 2008, 29:2270-2279.
106. Chen J., Saeky F., Wiley B.J., Cang H., Cobb M.J., Li Z.Y., et al. Gold nanocages: bioconjugation and their potential use as optical imaging contrast agents. Nano Lett 2005, 5:473-477.
107. Shukla R., Thomas T.P., Peters J.L., Desai A.M., Kukowska-Latallo J., Patri A.K., et al. HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb. Bioconjugate Chem 2006, 17:1109-1115.
108. Huh Y.M., Jun Y.W., Song H.T., Kim S., Choi J.S., Lee J.H., et al. In vivo magnetic resonance detection of cancer by using multifunctional magnetic nanocrystals. J Am Chem Soc 2005, 127:2387-2391.
109. Lee J.H., Huh Y.M., Jun J.W., Seo J.W., Jang J.T., Song H.T., et al. Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat Med 2007, 13:95-99.
110. Jun Y.W., Huh Y.M., Choi J.S., Lee J.H., Song H.T., Kim S., et al. Nanoscale size effect of magnetic nanocrystals and their utilization for cancer diagnosis via magnetic resonance imaging. J Am Chem Soc 2005, 127:5732-5733.
111. Song H.T., Choi J.S., Huh Y.M., Kim S., Jun Y.W., Suh J.S., et al. Surface modulation of magnetic nanocrystals in the development of highly efficient magnetic resonance probes for intracellular labeling. J Am Chem Soc 2005, 127:9992-9993.
112. ®) coupled nanoparticles. Int J Pharm 2007, 331:190-196.
113. Steinhauser I., Spänkuch B., Strebhardt K., Langer K. Trastuzumab-modified nanoparticles: optimization of preparation and uptake in cancer cells. Biomaterials 2006, 27:4975-4983.
114. Anhorn M.G., Wagner S., Kreuter J., Langer K., Von Briesen H. Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles. Bioconjugate Chem 2008, 19:2321-2331.
115. Artemov D., Mori N., Okollie B., Bhujwalla Z.M. MR molecular imaging of the HER2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Res Med 2003, 49:403-408.
116. Yezhelyev M.Y., Al-Hajj A., Morris C., Marcus A.I., Liu T., Lewis M., et al. In situ molecular profiling of breast cancer biomarkers with multicolor quantum dots. Adv Mater 2007, 19:3146-3151.
117. Yoon T.J., Yu K.N., Kim E., Kim J.S., Kim B.G., Yun S.H., et al. Specific targeting, cell sorting, and bioimaging with smart magnetic silica core-shell nanomaterials. Small 2006, 2:209-215.
118. Alexis F., Basto P., Levy-Nissenbaum E., Radovic-Moreno A.F., Zhang L., Pridgen E., et al. Her-2-targeted nanoparticle-affibody conjugates for cancer terapy. ChemMedChem 2008, 3:1839-1843.
119. Barat B., Sirk S.J., McCabe K.E., Li J., Lepin E.J., Remenyi R., et al. Cys-diabody quantum dot conjugates (immunoqdots) for cancer marker detection. Bioconjugate Chem 2009, 20:1474-1481.
120. Kim J., Kim H.S., Lee N., Kim T., Kim H., Yu T., et al. Multifunctional uniform nanoparticles composed of a magnetite nanocrystal core and a mesoporous silica shell for magnetic resonance and fluorescence imaging and for drug delivery. Angew Chem Int Ed 2008, 47:8438-8441.
121. Tsai C.-P., Chen C.-Y., Hung Y., Chang F.-H., Mou C.-Y. Monoclonal antibody-functionalized mesoporous silica nanoparticles (MSN) for selective targeting breast cancer cells. J Mater Chem 2009, 19:5737-5743.
122. Chen T.-J., Cheng T.-H., Chen C.-Y., Hsu S., Cheng T.-L., Liu G.-C., et al. Targeted Herceptin-dextran iron oxide nanoparticles for noninvasive imaging of HER2/neu receptors using MRI. J Biol Inorg Chem 2009, 14:253-260.
123. Lim Y.T., Cho M.Y., Choi B.S., Lee J.M., Chung B.H. Paramagnetic gold nanostructures for dual modal bioimaging and phototherapy of cancer cells. Chem Commun 2008, 4930-4932.
124. 4 nanoparticle "Nano-pearl-necklaces" for simultaneous targeting, dual-mode imaging, and photothermal ablation of cancer cells. Angew Chem Int Ed 2009, 48:2759-2763.
125. Yang Y., Yan X., Cui Y., He Q., Li D., Wang A., et al. Preparation of polymer-coated mesoporous silica nanoparticles used for cellular imaging by a "graft-from" method. J Mater Chem 2008, 18:5731-5737.
126. Lee J., Yang J., Seo S.-B., Ko H.-J., Suh J.-S., Huh Y.-M., et al. Smart nanoprobes for ultrasensitive detection of breast cancer via magnetic resonance imaging. Nanotechnology 2008, 19:485101.
127. Lee A.L.Z., Wang Y., Cheng H.Y., Pervaiz S., Yang Y.Y. The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles. Biomaterials 2009, 30:919-927.
128. Cheng S.-H., Lee C.-H., Yang C.-S., Tseng F.-G., Mou C.-Y., Lo L.-W. Mesoporous silica nanoparticles functionalized with an oxygen-sensing probe for cell photodynamic therapy: potential cancer theranostics. J Mater Chem 2009, 19:1252-1257.
129. Lim Y.T., Cho M.Y., Kim J.K., Hwangbo S., Chung B.H. Plasmonic magnetic nanostructure for bimodal imaging and photonic-based therapy of cancer cells. ChemBioChem 2007, 8:2204-2209.
130. Yang L., Peng X.-H., Wang Y.A., Wang X., Cao Z., Ni C., et al. Receptor-targeted nanoparticles for in vivo imaging of breast cancer. Clin Cancer Res 2009, 15:4722-4732.
131. Karathanasis E., Chan L., Balusu S.R., D'Orsi C.J., Annapragada A.V., Sechopoulos I., et al. Multifunctional nanocarriers for mammographic quantification of tumor dosing and prognosis of breast cancer therapy. Biomaterials 2008, 29:4815-4822.
132. Park H., Lee S., Chen L., Lee E.K., Shin S.Y., Lee Y.H., et al. SERS imaging of HER2-overexpressed MCF7 cells using antibody-conjugated gold nanorods. Phys Chem Chem Phys 2009, 11:7444-7449.
133. Lee S., Chon H., Lee M., Choo J., Shin S.Y., Lee Y.H., et al. Surface-enhanced Raman scattering imaging of HER2 cancer markers overexpressed in single MCF7 cells using antibody conjugated hollow gold nanospheres. Biosens Bioelectron 2009, 24:2260-2263.
134. Zhou J., Leuschner C., Kumar C., Hormes J.F., Soboyejo W.O. Sub-cellular accumulation of magnetic nanoparticles in breast tumors and metastases. Biomaterials 2006, 27:2001-2008.
135. Medarova Z., Rashkovetsky L., Pantazopoulos P., Moore A. Multiparametric monitoring of tumor response to chemotherapy by noninvasive imaging. Cancer Res 2009, 69:1182-1189.
136. Meng J., Fan J., Galiana G., Branca R.T., Clasen P.L., Ma S., et al. LHRH-functionalized superparamagnetic iron oxide nanoparticles for breast cancer targeting and contrast enhancement in MRI. Mater Sci Eng C 2009, 29:1467-1479.
137. Leuschner C., Kumar C., Hansel W., Soboyejo W., Zhou J., Hormes J. LHRH-conjugated magnetic iron oxide nanoparticles for detection of breast cancer metastases. Breast Cancer Res Treat 2006, 99:163-176.
138. Pan J., Feng S.-S. Targeting and imaging cancer cells by Folate-decorated, quantum dots (QDs)-loaded nanoparticles of biodegradable polymers. Biomaterials 2009, 30:1176-1183.
139. Kobayashi H., Koyama Y., Barrett T., Hama Y., Regino C.A.S., Shin I.S., et al. Multimodal nanoprobes for radionuclide and five-color near-infrared optical lymphatic imaging. ACS Nano 2007, 1:258-264.
140. Altinoglu E., Russin T.J., Kaiser J.M., Barth B.M., Eklund P.C., Kester M., et al. Near-infrared emitting fluorophore-doped calcium phosphate nanoparticles for in vivo imaging of human breast cancer. ACS Nano 2008, 2:2075-2084.
141. Haglund E., Seale-Goldsmith M.M., Leary J.F. Design of multifunctional nanomedical systems. Ann Biomed Eng 2009, 37:2048-2063.
142. Cho K.J., Wang X., Nie S.M., Chen Z., Shin D.M. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008, 14:1310-1316.
143. Yang J., Lee C.H., Park J., Seo S., Lim E.K., Song Y.J., et al. Antibody conjugated magnetic PLGA nanoparticles for diagnosis and treatment of breast cancer. J Mater Chem 2007, 17:2695-2705.
144. Yang J., Lee C.H., Ko H.J., Suh J.S., Yoon H.G., Lee K., et al. Multifunctional magneto-polymeric nanohybrids for targeted detection and synergistic therapeutic effects on breast cancer. Angew Chem Int Edit 2007, 46:8836-8839.
145. Sun B., Ranganathan B., Feng S.S. Multifunctional poly(d,l-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer. Biomaterials 2008, 29:475-486.
146. 4 nanoparticles for targeted delivery and controlled release of cisplatin. J Am Chem Soc 2009, 131:10637-10644.
147. 4 nanoparticles for target-specific platin delivery. J Am Chem Soc 2009, 131:4216-4217.
148. Xia Y., Rogers J.A., Paul K.E., Whitesides G.M. Unconventional methods for fabricating and patterning nanostructures. Chem Rev 1999, 99:1823-1848.
149. Skrabalak S.E., Chen J., Au L., Lu X., Li X., Xia Y. Gold nanocages for biomedical applications. Adv Mater 2007, 19:3177-3184.
150. Chen J.Y., Wang D.L., Xi J.F., Au L., Siekkinen A., Warsen A., et al. Immuno gold nanocages with tailored optical properties for targeted photothermal destruction of cancer cells. Nano Lett 2007, 7:1318-1322.
151. Hirsch L.R., Stafford R.J., Bankson J.A., Sershen S.R., Rivera B., Price R.E., et al. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci USA 2003, 23:13549-13554.
152. Huang X., El-Sayed I.H., Qian W., El-Sayed M.A. Cancer cell imaging and photothermal therapy in the Near-Infrared region by using gold nanorods. J Am Chem Soc 2006, 128:2115-2120.
153. Au L., Zheng D.S., Zhou F., Li Z.Y., Li X.D., Xia Y.N. A quantitative study on the photothermal effect of immuno gold nanocages targeted to breast cancer cells. ACS Nano 2008, 2:1645-1652.
154. Ito A., Kuga Y., Honda H., Kikkawa H., Horiuchi A., Watanabe Y., et al. Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia. Cancer Lett 2004, 212:167-175.
155. Le B., Shinkai M., Kitade T., Honda H., Yoshida J., Wakabayashi T., et al. Preparation of tumor-specific magnetoliposomes and their application for hyperthermia. J Chem Eng Jpn 2004, 34:141-150.
156. Kikumori T., Kobayashi T., Sawaki M., Imai T. Anti-cancer effect of hyperthermia on breast cancer by magnetite nanoparticle-loaded anti-HER2 immunoliposomes. Breast Cancer Res Treat 2009, 113:435-441.
157. Hilger I., Dietmar E., Linss W., Streck S., Kaiser W.A. Developments for the minimally invasive treatment of tumours by targeted magnetic heating. J Phys: Condens Matter 2006, 18:S2951-S2958.
158. Takahashi S., Ito Y., Hatake K., Sugimoto Y. Gene therapy for breast cancer. Review of clinical gene therapy trials for breast cancer and MDR1 gene therapy trial in Cancer Institute Hospital. Breast Cancer 2006, 13:8-15.
159. Yu W.Y., Zhang N. Surface modification of nanocarriers for cancer therapy. Curr Nanosci 2009, 5:123-134.
160. Wang V., Wu W. MicroRNA-based therapeutics for cancer. BioDrugs 2009, 23:15-23.
161. Buxton D.B. Nanomedicine for the management of lung and blood diseases. Nanomedicine 2009, 4:331-339.
162. Hayes M.E., Drummond D.C., Kirpotin D.B., Zheng W.W., Noble C.O., Park J.W., et al. Genospheres: self assembling nucleic acid-lipid nanoparticles suitable for targeted gene delivery. Gene Ther 2006, 13:646-651.
163. Hayes M.E., Drummond D.C., Hong K., Zheng W.W., Khorosheva V.A., Cohen J.A., et al. Increased target specificity of anti-HER2 genospheres by modification of surface charge and degree of PEGylation. Mol Pharm 2006, 3:726-736.
164. Tan W.B., Jiang S., Zhang Y. Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference. Biomaterials 2007, 28:1565-1571.
165. Spänkuch B., Steinhauser I., Wartlick H., Kurunci-Csacsko E., Strebhardt K.I., Langer K. Down-regulation of Plk1 expression by receptor-mediated uptake of antisense oligonucleotide-loaded nanoparticles. Neoplasia 2008, 10:223-234.
166. Steinhauser I., Spänkuch B., Strebhardt K.I., Langer K. Trastuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells. Biomaterials 2006, 27:4975-4983.
167. Wang Y., Sriramchandra S., Mangipudi S., Canine B.F., Hatefi A. A designer biomimetic vector with a chimeric architecture for targeted gene transfer. J Control Rel 2009, 137:46-53.
168. Kirchner C., Liedl T., Kudera S., Pellegrino T., Javier A.M., Gaub H.E., et al. Cytotoxicity of colloidal CdSe and CdSe/ZnS nanoparticles. Nano Lett 2005, 5:331-338.
169. Derfus A.M., Chan W.C.W., Bathia S.N. Probing the cytotoxic of semiconductor quantum dots. Nano Lett 2004, 4:11-18.
170. Maysinger D., Behrendt M., Lalancette-Herbert M., Kriz J. Real-time imaging of astrocyte response to quantum dots: in vivo screening model system for biocompatibility of nanoparticles. Nano Lett 2007, 7:2513-2520.
171. Cho S.J., Maysinger D., Jain M., Roder B., Hackbarth S., Winnick F.M. Long-term exposure to CdTe quantum dots causes functional impairments in live cells. Langmuir 2007, 23:1974-1980.
172. Lovric J., Cho S.J., Winnick F.M., Maysinger D. Unmodified cadmium telluride quantum dots induce reactive oxygen species formation leading to multiple organelle damage and cell death. Chem Biol 2005, 12:1227-1234.
173. Smith A.M., Duan H.W., Rhyner M.N., Ruan G., Nie S.M. A systematic examination of surface coatings on the optical and chemical properties of semiconductor quantum dots. Phys Chem Chem Phys 2006, 8:3895-3903.